# HSEF v5.3 review: Genome Instability: Root Cause vs Consequence

> Sources: 61 primary reports; claims: 66; verified: 66; unverified: 0. Verification is bounded attribution. Access: 8 partial-body and 53 complete abstract/status examinations. Literature cutoff: 2026-10-08; source examination UTC date: 2026-10-09. No complete-paper audit or blinded calibration claimed.
> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 6 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.**

## AT A GLANCE

**Genome instability can cause susceptibility and accelerate selected cancers; its general initiating primacy is unproved.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Γ — Mechanistically plausible, partial system support | Moderate | reinforcing / stabilizing factor | Mechanistic only | Stable | Contested |

**Deciding experiment:** Across prospectively defined sporadic tissues, trace native clones before transformation while measuring division-level mutation/segregation rates and driver activation. Selectively normalize the relevant rate without removing fixed drivers or changing p53, proliferation or centrosome signaling; reinstate the rate and repeat in independent autochthonous models.

**Belief versus evidence:** The preregistered general-root gate SC4 remains Γ. Endogenous repair and segregation perturbations establish defined cancer-susceptibility routes (SC2 Ζ), and rate-specific progression or resistance interventions support context-valid causality (SC3 Ε). Associations and fixed abnormal states cannot establish the temporal root of all cancer.

**Best-supported rival:** Context-dependent evolutionary accelerator. Silk rate-stratified endogenous contrasts, Levine versus Vitre centrosome models and transient CIN/p53 stratification separate generalized instability-first claims from context-dependent promotion, suppression or no change (PMID 24133140, 28132847, 26578792, 34266887).

## COMPETING MECHANISTIC MODELS

**Rank 1: Context-dependent evolutionary accelerator (Ε).** Instability supplies selectable diversity or signaling in already susceptible or oncogene-driven tumors. Rate correction with retained aneuploid burden, resistance contrasts and recurrence models discriminate stage-specific roles (PMID 29342134, 35905505, 20173739). This winner is scoped to tested progression and selection settings, not a new universal origin.

**Rank 2: Oncogene-first stress with barrier escape (Ε).** Upstream oncogenic activity creates replication/segregation stress, and checkpoint barriers determine survival. RAS/MAPK and HER2 interventions, early damage responses and ATM-barrier disruption establish this direction in defined models (PMID 10951588, 27634334, 17136093). Culture and engineered models do not determine the fraction of human sporadic initiation attributable to this route.

**Rank 3: Genome-stress immune signaling (Ε).** Cytosolic DNA changes tumor and host immune states with context-dependent consequences. STING epistasis and immune-competent versus deficient hosts support specific pathways (PMID 37612508, 33372007, 33338425). CIN-associated immunosuppression and MMR-linked immune rejection differ; pathway activation alone does not imply a universal outcome.

**Rank 4: Rate-dependent fitness and tumor barrier (Ζ).** Excess instability or stress can impair viability and tumor progression. Measured CENP-E/Mad2 high-error contrasts and independent INO80/Apc fork-stress course changes support bounded suppressive mechanisms (PMID 24133140, 27146113, 29383140). These are independent error families but not a universal quantitative threshold; low and high rates, mutation classes and tissues differ.

**Rank 5: General instability-first root (Γ).** Instability can precede and enable transforming changes. Inherited endogenous repair defects and forced mitotic perturbations support genuine initiating capacities (PMID 7628020, 28132847). Capacities and susceptibility do not establish general primacy, continued necessity or all-context sufficiency.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Ongoing genome instability is the primary root cause of cancer initiation and malignant progression rather than a consequence of oncogenic transformation or a context-dependent accelerator.

Ranking labels this entry Cancer Biology. The index genome-instability entry instead concerns aging; that scope is not silently imported. Distinguish instability rate from fixed driver mutations, repair-deficiency initiation from acquired chromosomal instability, and contributing evolution from universal primacy.

Selection: public-interest rank 39 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

### Evidence and causal interpretation

The registered cancer-specific review distinguishes ongoing genome change from the abnormal genome that remains afterward. Sixty-one original reports span endogenous repair defects, mitotic mechanisms, upstream oncogenes, resistance and negative tumor outcomes. The broad general-root claim is not silently replaced with the easier assertion that some genome-maintenance defects predispose cancer.

Msh2 loss generates a mutator phenotype in normal tissues and tumor susceptibility (PMID 7628020, 9244348, 8706033). Reporter measurements are mutation frequencies, not per-division rates. Mlh1 cell complementation reduces substitutions and microsatellite changes (PMID 9973196), while Msh2 loss accelerates Apc-driven adenomas (PMID 8674041). These establish repair function and susceptibility; they do not establish instability as an immediate sufficient transforming event or a universal sporadic root.

Conditional Brca1, Brca2-domain and FEN1-domain models add endogenous susceptibility with distinct repair mechanisms (PMID 11376699, 11861370, 21383776). Long latency, cooperating p53 alterations and coupled replication/growth/checkpoint functions remain. USP44 and BubR1 studies identify spontaneous or driver-associated susceptibility (PMID 23187126, 23878276, 15767571), yet kinase-dead Bub1 produces substantial errors without increased tumors (PMID 23209306). A repair or checkpoint gene mutation is not automatically evidence that one instability rate mediates all of its cancer effect.

Sotillo forced Mad2 expression produces tumors, but serial MRI shows 12 established tumors continue after the Mad2 transgene is reduced (PMID 17189715). The source demonstrates that the inducing transgene is not continuously required. It does not prove every instability process in the resulting tumor has stopped. Transient Plk4 exposure in p53-stratified mice similarly supports selected-karyotype evolution after an error pulse (PMID 34266887): p53-wild-type survival and tumor frequency do not increase, whereas p53-deficient thymic lymphoma accelerates.

Levine finds spontaneous tumors after chronic or transient inducible Plk4 exposure and more ApcMin tumors without greater size (PMID 28132847). Vitre finds centrosome amplification and increased abnormal mitoses without additional tumor-course effects in its p53 and skin-carcinogen settings (PMID 26578792). The exposure, tissue expression, competing lethal tumors and p53 surveillance differ, so this is a contextual tension rather than a direct replication failure. Centrosome-driven Rac1 invasion and fly asymmetric-division tumors also show non-CIN routes (PMID 24739973, 18555779).

Silk directly relates missegregation to outcome (PMID 24133140). Combined CENP-E/Mad2 perturbation raises error and cell-death rates while reducing selected tumors. In Ink4a and MLH1 contexts, added CENP-E-dependent missegregation changes chromosome abnormalities without changing tumor-free survival or course. Zasadil distinguishes increased initiating organoids from suppressed later progression in ApcMin tissue (PMID 27146113). Independent INO80 fork stress activates a checkpoint/apoptosis barrier and reduces Apc polyps (PMID 29383140). No universal fatal-error threshold is inferred across these mutation classes.

Bakhoum provides an especially useful rate-versus-state experiment (PMID 29342134). KIF2B or MCAK reduces measured errors and metastasis while cells remain highly aneuploid; KIF2A, proliferation and centrosome-number controls address competing effects, and Mad2 partially reinstates metastatic output. Primary growth does not consistently decline. Cytosolic-DNA and STING/noncanonical NF-kB interventions support a specific metastatic pathway, not general tumor initiation.

Li and colleagues extend this programme to tumor-host signaling (PMID 37612508). CIN-driven metastatic differences are far greater in immune-competent than severely immune-compromised hosts; STING/cGAS and ER-stress interventions dissect the pathway, with tumor-intrinsic STING controls for drug effects. ENPP1 work connects extracellular cGAMP to host signaling (PMID 33372007). These are coherent selected systems but share models and a programme, and cannot be counted as three independent demonstrations of a universal mechanism.

CIN supplies selectable resistance in drug-treated models (PMID 34352222, 35905505, 38871738). Fixed chromosome loss or 1q dependency can be causal without continual instability being required (PMID 37410869). Chromothripsis and ecDNA experiments identify ways new resistance states arise (PMID 26017310, 33361815, 39181133). Human ovarian and osteosarcoma genome histories refine ongoing evolution (PMID 40670783, 39814020), but reconstructed history is not an initiation intervention.

In Kras/Mad2 lung tumors, initial withdrawal still causes regression; later recurrence occurs in 11 of 24 double-inducible animals, with bypass signaling and mostly no transgene re-expression (PMID 20173739). The original authors formally retain possible de novo tumors; co-localized MRI and exposure controls argue against that alternative without lineage proof. Recurrence-associated aneuploidy is not a direct ongoing-rate measurement. This supports an accelerator model in established disease, not instability as the first cause.

RAS/MAPK and HER2 perturbations place oncogenic signaling upstream of errors, replication stress or APOBEC activity in specified models (PMID 10608877, 10951588, 27634334). Early-lesion damage responses and ATM/senescence interventions show protective barriers (PMID 15829956, 17136093, 17136094). Human early-lesion staging is cross-sectional, and activity changes are not automatically mutation-rate changes, but these routes directly contest an obligatory instability-first sequence.

MMR deficiency also has immune consequences: Exo1-dependent cytosolic DNA and STING affect response, and changing repair-deficient fractions can enable rejection in selected mixtures (PMID 33338427, 33338425, 36584674). Greater instability is therefore not uniformly tumor promoting. The tournament favors a context-dependent accelerator, with driver-induced stress and host signaling as complementary causal routes. The exact general-root claim remains Γ while defined susceptibility reaches Ζ and selected progression reaches Ε.

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

<!-- consensus-consistency-2026-10-09 -->
### Consensus provenance reconciliation — 9 October 2026

Case-specific Consensus discovery records were located and linked to this final edition. This supplements the review's provenance; it leaves the original assessed claim, grades and source counts intact. Provider summaries and full-text badges do not establish examination of original primary passages by this reviewer. Source access and incorporation retain the limits stated in the original methods and any dated research update.

Recorded evidence artifacts:

- `deliverables/hsef_v53_popularity_ranks_36_40_2026-10-08/genome-instability-cancer/consensus/broad-ax.txt`
- `deliverables/hsef_v53_popularity_ranks_36_40_2026-10-08/genome-instability-cancer/consensus/RECONCILIATION.md`
- `deliverables/hsef_v53_popularity_ranks_36_40_2026-10-08/genome-instability-cancer/consensus/targeted-ax.txt`
- `deliverables/hsef_v53_popularity_ranks_36_40_2026-10-08/genome-instability-cancer/consensus/usage.json`

Reported usage is preserved in the linked source-specific records; query counts and original-passage comparisons are different measures.

No earlier adversarial approval is attached to this case; this provenance supplement is not a new independent or blinded adjudication, and nothing earlier certifies it. No score or confidence change is made by this reconciliation.
<!-- end-consensus-consistency -->


### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Genome instability occurs in established cancers. | tumor lineage, stage and measured mutation/segregation rate | Β | Tumor genomes and direct cell-division assays establish that changing genomes exist; mere occurrence is descriptive under the causal rubric. Burden, frequency and inferred historical process are distinguished from per-division rate. |
| SC2 Endogenous repair/segregation defects can initiate cancers. | specific lesion and tissue genotype | Ζ | Endogenous MMR, repair-domain and segregation-gene models, normal-tissue mutator measurements and cell repair complementation converge on defined susceptibility. Gene pleiotropy, cooperating drivers and tissue-specific negative outcomes bound the conclusion; susceptibility is not immediate sole transformation. |
| SC3 Ongoing instability contributes to progression or metastasis. | instability subtype, stage and rate defined before outcome | Ε | Measured rate correction changes metastasis independently of karyotypic burden, and CIN manipulations alter resistance and recurrence in specified oncogene/treatment models. Most interventions are engineered or transplant based; host dependence, shared programmes and lack of matched independent autochthonous rate-restoration course tests prevent a field-wide upper grade. |
| SC4 Genome instability is the general primary root cause of cancer. | representative prespecified cancer etiologies and stages | Γ | Mechanistic and in vivo causal contributions make a broad instability-first model plausible, but no matching evidence establishes general primacy over upstream oncogenes or context-dependent amplification. Negative endogenous models and transient initiation with continued tumor growth distinguish contribution from obligatory ongoing root. |

Preregistered aggregation: primary-subclaim. The preregistered general-root gate SC4 remains Γ. Endogenous repair and segregation perturbations establish defined cancer-susceptibility routes (SC2 Ζ), and rate-specific progression or resistance interventions support context-valid causality (SC3 Ε). Associations and fixed abnormal states cannot establish the temporal root of all cancer. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

### Decisive-perturbation inventory and causal tally

[1] CIN rate and cGAS-STING/ER-stress perturbations alter metastasis through host immune context. Same Bakhoum programme as 2018; engineered transplant models establish progression not all-cancer initiation.

[2] KIF2B/MCAK lower measured missegregation without normalizing aneuploid burden; metastasis falls and Mad2 partially restores it. Primary growth does not consistently fall; forced rate correction and transplantation do not establish universal endogenous initiation.

[3] ENPP1 loss and host STING epistasis link extracellular cGAMP handling to metastasis and immune recruitment. Downstream immune mechanism rather than proof that CIN initiates cancer; shared programme.

[8] USP44 loss causes segregation defects and spontaneous lung tumors; centrin interaction separates centrosome positioning from checkpoint delay. USP44 has multiple functions; endogenous model supports a defined initiating route, not a general root.

[10] BubR1 insufficiency increases chromosome errors and colon tumor incidence and grade with an Apc driver. Genetic interaction and checkpoint functions are coupled; no claim that instability alone initiates all cancers.

[13] Transient CIN generates recurrent aneuploid resistant clones; a specified chromosome loss confers paclitaxel resistance. Fixed resistant state is distinct from continued rate dependence; selected treatment context.

[15] Whole-genome doubling and copy-number routes alter targeted-treatment responses. Treatment-selected evolution and existing drivers; not untreated initiating primacy.

[17] RanGAP1 dysregulation couples mitotic disruption, chromothripsis, Rb1 disruption and rapid osteosarcoma. Protein transport, p53 degradation and segregation are coupled; the initiating mechanism is not isolated instability alone.

[18] CIN promotes escape through MET amplification and creates a new cMet dependency. Established oncogene-driven and withdrawal-selected disease; not original initiation.

[19] Reducing CIN changes resistance timing and copy-number routes without changing initial xenograft growth. Resistance-specific engineered models; transplant growth alone cannot establish endogenous initiating necessity.

[22] Removing recurrent trisomy 1q impairs malignant growth through an MDM4-p53 axis. Dependency on a fixed chromosome state is not dependence on the rate of genome change.

[26] Defective PCNA interaction compromises replication/repair and increases instability, transformation and tumors. Repair, replication and checkpoint functions change together; cell-level Chk1 inhibition is not whole-animal repair restoration.

[27] Defined tissues show spontaneous tumor promotion while other contexts show suppression. Abstract-only; tissue-specific opposing outcomes and shared CENP-E model family limit generalization.

[31] Exo1-dependent hyperexcision links MMR loss to cytosolic DNA and STING. Repair loss can trigger opposing immune consequences; not a universal tumor-promoting root.

[33] cGAS/STING governs priming and checkpoint response in repair-defective tumors. Downstream immune context and pre-established tumors; greater instability can favor host control.

[34] MLH1 manipulation changes resistant mutation frequencies and growth-factor/drug dependence. Cell restoration plus patient association do not establish prospective human tumor prevention.

[35] Endogenous Brca1 loss predisposes mammary tumors with later cooperating alterations. Long latency and p53 mutations; essential repair, growth and apoptosis functions cannot be reduced to one rate.

[36] Viable homozygous domain-mutant animals develop more tumors and shorter survival. Domain perturbation has coupled functions; no genotype-matched full repair restoration establishes all-cancer primacy.

[37] Mad2-induced instability promotes diverse tumors but 12 imaged tumors continue growing after Mad2 withdrawal. Forced expression and long latency; withdrawing the inducer does not prove all residual instability disappears.

[38] A short CIN pulse accelerates thymic lymphoma in p53-deficient contexts and yields selected karyotypes. Wild-type p53 mice show no survival/tumor increase; ongoing instability is not obligatory once selected states arise.

[39] Combined endogenous repair/checkpoint defects accelerate lymphoma with structural and numerical errors. Genetic interaction with an existing driver; repair and checkpoint effects are coupled.

[42] Chronic or transient induction yields persistent centrosome amplification and spontaneous tumors; ApcMin tumor number rises. Forced inducible system; tissue expression varies, p53 signaling is partly compromised in tumors and CIN-specific pleiotropy is not entirely excluded.

[45] Noncanonical Fanconi machinery promotes micronuclear fragmentation and ecDNA-associated resistance. Pathway effects differ between micronuclei and interphase nuclei; treatment-selected cell models.

[47] Chromothripsis generates ecDNA amplification and selectable resistance with DNA-repair perturbations. Treatment selection and cell models; linked erratum details unexamined.

[48] Micronuclear replication/segregation can generate chromothripsis within one cell cycle. Demonstrates process capacity, not a general initiating or maintenance necessity in patients.

[52] Repair deficiency accelerates adenomas and changes routes of Apc inactivation. Inherited Apc driver already present; not instability-alone initiation or all-cancer necessity.

[53] Normal tissues accumulate greater reporter mutation frequencies after endogenous repair loss. Frequency per sampled tissue is not per-division rate; reporter and tissue selection limit generalization.

[54] MLH1 restoration decreases substitution/microsatellite mutation and restores associated MMR functions. Repair rescue in cultured cells is not a prevention or regression experiment in tumors.

[55] Repair loss establishes a mutator/recombination phenotype and tumor susceptibility. Predisposition and essential repair changes do not identify instability as the sole immediate transforming lesion.

[56] Lymphoma and intestinal tumors accrue with endogenous repair loss and Apc inactivation. Same Msh2 model family as 1995; not independent genetic replication or universal cancer causation.

[57] Checkpoint defects increase micronuclei and carcinogen-associated adenoma incidence. Carcinogen context and pleiotropic checkpoint function; spontaneous all-cancer root not tested.

[58] A domain mutation weakens checkpoint/attachment fidelity and raises spontaneous tumor susceptibility. Mutant mimics a regulatory defect with multiple consequences and selected cooperating p53 changes.

[60] Improving segregation fidelity protects against aneuploidy and cancer in tested contexts. Domain mechanisms and tissue scope differ from simple checkpoint-strength assumptions.

[61] Mad2 coexpression increases progression and later recurrence after both transgenes are withdrawn, without blocking initial Kras-dependent regression. Aneuploid burden at recurrence is not an ongoing measured rate; de novo recurrence cannot be formally excluded and model is forced.

Tally: 34 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Positive susceptibility sources cannot be tallied as positive evidence for general primacy. Negative or null contrasts do not inflate positive-support counts.

### Cap audit, precedence and Β/Γ/Δ boundary

Whole-case convergence supports Ζ for defined susceptibility and for bounded suppressive barriers; a cell-only cap cannot erase the assembled endogenous evidence. The same sources cannot upgrade the exact general-root gate. Progression is Ε because direct rate and course controls are valid but shared transplant programmes and engineered treatment models limit independent endogenous generalization.

Gamma hard-rule audit: Fixed aneuploid states, driver mutations, inferred signatures and mutation frequency are not automatically rates. CIN perturbations must retain proliferation, centrosome/cytoskeletal effects and initial tumor burden controls. Forced Mad2/Plk4 experiments establish capacity at their exposure and tissue scope, not all sporadic origin. Transgene withdrawal does not establish that every remaining instability process is zero. Initiation, maintenance, metastasis and treatment escape require different causal endpoints.

SC1 cap: “Association-only cancer claims cap at Β.” Tumor genomes and direct cell-division assays establish that changing genomes exist; mere occurrence is descriptive under the causal rubric. Burden, frequency and inferred historical process are distinguished from per-division rate.

SC4 cap: “Mechanistically plausible cell culture or transplantation-linked models without endogenous in vivo dependency cap at Γ.” Mechanistic and in vivo causal contributions make a broad instability-first model plausible, but no matching evidence establishes general primacy over upstream oncogenes or context-dependent amplification. Negative endogenous models and transient initiation with continued tumor growth distinguish contribution from obligatory ongoing root.

SC1 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Tumor genomes and direct cell-division assays establish that changing genomes exist; mere occurrence is descriptive under the causal rubric. Burden, frequency and inferred historical process are distinguished from per-division rate.

SC2 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: yes. Endogenous MMR, repair-domain and segregation-gene models, normal-tissue mutator measurements and cell repair complementation converge on defined susceptibility. Gene pleiotropy, cooperating drivers and tissue-specific negative outcomes bound the conclusion; susceptibility is not immediate sole transformation.

SC3 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: yes. Measured rate correction changes metastasis independently of karyotypic burden, and CIN manipulations alter resistance and recurrence in specified oncogene/treatment models. Most interventions are engineered or transplant based; host dependence, shared programmes and lack of matched independent autochthonous rate-restoration course tests prevent a field-wide upper grade.

SC4 field-valid definition: “
- Endogenous genetic manipulation in autochthonous models
- Patient-derived system perturbation with matched rescue AND in vivo confirmation
- Clonal tracking demonstrating persistence of dependency through selection pressure” Positive full-scope result: no. Mechanistic and in vivo causal contributions make a broad instability-first model plausible, but no matching evidence establishes general primacy over upstream oncogenes or context-dependent amplification. Negative endogenous models and transient initiation with continued tumor growth distinguish contribution from obligatory ongoing root.

### Upward threshold ladder

SC1 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. Separate description from causality: measure a predefined endogenous rate before transformation and show that selective rate correction changes a cancer endpoint.

SC2 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: yes. 

SC2 Ε: “Requires context-specific causal validity with explicit limits. Cancer stem cells often belong here when a stem-like hierarchy exists in some tumor contexts but fails as a universal model.” Satisfied: yes. 

SC2 Ζ: “Requires:
- Independent causal confirmation across models
- Reduced viability of major alternatives
- Relevance beyond one assay class” Satisfied: yes. 

SC2 Η: “Requires:
- Strong endogenous evidence
- Therapeutic or mechanistic consequence
- Reproducibility across disease settings within the claimed scope” Satisfied: no. Complete genotype-matched repair/segregation restoration in independent spontaneous lineages with directly measured rates and initiation endpoints; separate pleiotropic functions.

SC3 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: yes. 

SC3 Ε: “Requires context-specific causal validity with explicit limits. Cancer stem cells often belong here when a stem-like hierarchy exists in some tumor contexts but fails as a universal model.” Satisfied: yes. 

SC3 Ζ: “Requires:
- Independent causal confirmation across models
- Reduced viability of major alternatives
- Relevance beyond one assay class” Satisfied: no. Replicate independent post-onset rate restoration in autochthonous tumors with clonal tracking, preserved driver signaling and host-immune controls.

SC4 Δ: “Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.” Satisfied: no. Prospectively compare instability-first with driver-first trajectories across predefined sporadic tissues and selectively normalize rates before initiation, preserving other gene functions, followed by rescue/reinstatement.

Upper ladder: Endogenous repair/segregation genetics, normal-tissue longitudinal mutation measurements, selective repair restoration, clonal tracking and prophylactic or therapeutic tumor-course rescue are valid upper-ladder routes. No RCT-only requirement is imposed. Current successes establish scoped pathways, not universal primacy.

Independence: Susceptibility convergence spans repair defects, domain perturbations and segregation mechanisms rather than counting papers. Suppression convergence spans a shared high-CIN programme and an independent fork-stress pathway. Bakhoum/Li/ENPP1 share a programme; TRACERx-derived samples and Msh2 follow-ups are grouped. Negative outcomes are discriminators, not positive-root tallies.

Endogenous MMR susceptibility [55, 53, 54]: Normal-tissue mutator frequency and cell complementation test repair function; follow-up mice share the founding line.

Endogenous repair-domain models [35, 36, 26]: Conditional BRCA and FEN1 domain perturbations use different repair proteins and cancer lineages; multiple functions remain coupled.

Segregation-specific genetic contexts [8, 58, 60]: USP44 positioning and BubR1 attachment/checkpoint mechanisms use different perturbations and selected course endpoints.

Measured high-error suppression [7, 6]: Direct missegregation and apoptosis/course contrasts; shared CENP-E programme is one family.

Independent replication-stress barrier [30]: INO80 fork-stress/checkpoint effects reduce Apc tumor progression and improve survival through an error family distinct from CENP-E.

### Falsification and pitfalls

Disease occurs without the claimed obligatory feature. Mad2-induced tumors continue growing after Mad2 induction is withdrawn, and a transient CIN pulse can precede tumors; neither experiment proves every residual error process is absent (PMID 17189715, 34266887). Additional downgrade: False.

State substituted for rate. Fixed chromosome addiction, copy-number signatures and reporter mutation frequency receive separate limitations.

Initiation conflated with later selection. Metastasis, drug resistance and Kras recurrence never become all-cancer initiation evidence.

Perturbation pleiotropy ignored. Centrosome invasion, p53 signaling, BRCA and checkpoint gene functions are separated where possible.

Negative evidence ignored. Bub1, p53-wild-type transient CIN, Ink4a/MLH1 and Vitre contrasts are retained.

Provider output promoted to original evidence. Review-heavy timeline and gap matrix are discovery only; three named claims are compared with originals.

### Adversarial steelman: above, then below

One rung higher Δ: endogenous mutator and segregation models demonstrate that instability-related mechanisms can materially initiate cancer susceptibility.

One rung lower Β: genome abnormalities are merely correlates. That ignores causal genetics, functional repair complementation and rate-specific course changes.

The nominal mechanism exceeds association, so Β is too low. Δ would require evidence matching its general-root primacy, not transfer from selected susceptibility or progression cases. Preserve Γ for SC4 and higher narrow grades.

### Final score, causal direction and M/S/D

The preregistered general-root gate SC4 remains Γ. Endogenous repair and segregation perturbations establish defined cancer-susceptibility routes (SC2 Ζ), and rate-specific progression or resistance interventions support context-valid causality (SC3 Ε). Associations and fixed abnormal states cannot establish the temporal root of all cancer.

Supported ongoing instability supplies diversity and feedback that can sustain progression or escape. Defined inherited mutator defects can confer initiating susceptibility, but neither that narrower etiological role nor all-context necessity is assigned to the general root claim.

Momentum: Mechanistic only. Examined 2025 ovarian genome/imaging and 2025 live division-to-genome studies improve temporal/rate resolution; no future outcome is presumed (PMID 40670783, 41162705). Both are completed publications rather than work being run, and neither addresses the general-primacy boundary check, so the stronger value is not available.

Stability: Stable. No specific pending result is claimed to move the general-root grade imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

Across prospectively defined sporadic tissues, trace native clones before transformation while measuring division-level mutation/segregation rates and driver activation. Selectively normalize the relevant rate without removing fixed drivers or changing p53, proliferation or centrosome signaling; reinstate the rate and repeat in independent autochthonous models.

Readout: Clonal initiation hazard, driver timing, measured rates, tumor latency, primary growth, metastasis and treatment-free trajectory. Controls: Driver-matched rate-stable controls, equal proliferation, host immune strata, abundance-matched allele restoration, negative lineages and blinded serial tracking. Supporting: Selective rate normalization prevents initiation across predefined settings and rate reinstatement restores it before driver acquisition; post-onset dependence is separately demonstrated. Falsifying: Initiation proceeds with normalized rates or instability consistently follows driver activation; only resistance or metastasis changes in restricted contexts.

## RESEARCH TIMELINE

| Year | Milestone | Primary source | Interpretation |
|---|---|---|---|
| 1995 | Endogenous MMR susceptibility | [PMID 7628020](https://pubmed.ncbi.nlm.nih.gov/7628020/) | Mutator phenotype and tumors. |
| 1996 | Repair and Apc interaction | [PMID 8674041](https://pubmed.ncbi.nlm.nih.gov/8674041/) | Existing driver and mutation route. |
| 1997 | Normal-tissue mutator reporter | [PMID 9244348](https://pubmed.ncbi.nlm.nih.gov/9244348/) | Frequency distinct from rate. |
| 1999 | Repair complementation | [PMID 9973196](https://pubmed.ncbi.nlm.nih.gov/9973196/) | Cell-level function restored. |
| 1999 | RAS-induced errors | [PMID 10608877](https://pubmed.ncbi.nlm.nih.gov/10608877/) | Upstream-driver direction. |
| 2001 | Conditional Brca1 susceptibility | [PMID 11376699](https://pubmed.ncbi.nlm.nih.gov/11376699/) | Latency and cooperating changes. |
| 2002 | Brca2 domain susceptibility | [PMID 11861370](https://pubmed.ncbi.nlm.nih.gov/11861370/) | Endogenous repair-domain scope. |
| 2005 | Early damage response | [PMID 15829956](https://pubmed.ncbi.nlm.nih.gov/15829956/) | Cross-sectional barrier evidence. |
| 2006 | Oncogene-triggered senescence | [PMID 17136094](https://pubmed.ncbi.nlm.nih.gov/17136094/) | Replication stress before escape. |
| 2007 | Tissue-dependent CENP-E outcomes | [PMID 17189716](https://pubmed.ncbi.nlm.nih.gov/17189716/) | Promotion and suppression. |
| 2007 | Mad2 induction and withdrawal | [PMID 17189715](https://pubmed.ncbi.nlm.nih.gov/17189715/) | Initiation separated from maintenance. |
| 2008 | Centrosome non-CIN tumor route | [PMID 18555779](https://pubmed.ncbi.nlm.nih.gov/18555779/) | Asymmetric division context. |
| 2010 | CIN-associated Kras recurrence | [PMID 20173739](https://pubmed.ncbi.nlm.nih.gov/20173739/) | Initial regression retained. |
| 2012 | USP44 endogenous susceptibility | [PMID 23187126](https://pubmed.ncbi.nlm.nih.gov/23187126/) | Segregation mechanism. |
| 2012 | Bub1 negative cancer control | [PMID 23209306](https://pubmed.ncbi.nlm.nih.gov/23209306/) | Errors without extra tumors. |
| 2013 | Rate-dependent tumor outcomes | [PMID 24133140](https://pubmed.ncbi.nlm.nih.gov/24133140/) | High-error suppression and null contexts. |
| 2015 | Plk4 no-added-tumor model | [PMID 26578792](https://pubmed.ncbi.nlm.nih.gov/26578792/) | Timing/tissue boundary. |
| 2016 | Initiation versus progression | [PMID 27146113](https://pubmed.ncbi.nlm.nih.gov/27146113/) | High CIN suppresses later growth. |
| 2017 | Plk4 tumor-positive model | [PMID 28132847](https://pubmed.ncbi.nlm.nih.gov/28132847/) | Persistent centrosome amplification. |
| 2018 | Rate-specific metastasis | [PMID 29342134](https://pubmed.ncbi.nlm.nih.gov/29342134/) | Aneuploid burden remains. |
| 2019 | Genome-crisis immune barrier | [PMID 30675059](https://pubmed.ncbi.nlm.nih.gov/30675059/) | Autophagy and STING. |
| 2020 | CIN bypass of Kras dependence | [PMID 32030896](https://pubmed.ncbi.nlm.nih.gov/32030896/) | MET amplification. |
| 2021 | Transient CIN and p53 | [PMID 34266887](https://pubmed.ncbi.nlm.nih.gov/34266887/) | Genotype-specific progression. |
| 2021 | ecDNA resistance formation | [PMID 33361815](https://pubmed.ncbi.nlm.nih.gov/33361815/) | Drug-selected chromothripsis. |
| 2022 | CIN and resistance timing | [PMID 35905505](https://pubmed.ncbi.nlm.nih.gov/35905505/) | No initial growth effect. |
| 2023 | Tumor-host signaling | [PMID 37612508](https://pubmed.ncbi.nlm.nih.gov/37612508/) | Immune-context dependence. |
| 2023 | Fixed chromosome addiction | [PMID 37410869](https://pubmed.ncbi.nlm.nih.gov/37410869/) | State is distinct from rate. |
| 2025 | Ovarian genome trajectories | [PMID 40670783](https://pubmed.ncbi.nlm.nih.gov/40670783/) | History plus imaging. |
| 2025 | Division-to-genome measurement | [PMID 41162705](https://pubmed.ncbi.nlm.nih.gov/41162705/) | Direct process resolution. |

## KNOWLEDGE GAPS

Measure native pre-transformation rates rather than infer them from burden.

Separate repair and checkpoint pleiotropy using modular allele restoration.

Reconcile positive and negative Plk4 models with matched timing, tissue dosage and p53 surveillance.

Trace residual clones in CIN-associated recurrence to exclude de novo tumors.

Independently replicate post-onset rate correction in autochthonous disease.

Separate tumor-intrinsic and host cGAS-STING responses over time.

Map mutation-class-specific promotion/suppression thresholds prospectively.

Distinguish fixed aneuploid-state dependency from continual-rate dependency.

Follow normal inherited-mutator tissues longitudinally to the immediate transforming event.

Audit linked errata, supplements and inaccessible bodies before complete-paper publication claims.

## METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Provider statements about Methods/Results and any returned passages were compared with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful original-passage comparisons are distinguished from provider summaries and assertions of access. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

## REVIEWER NOTES

61 primary reports; eight selected partial-body examinations and 53 complete abstract/status examinations. One research-news record was excluded after inspection. No complete-paper audit or independent blinded review; two linked correction details remain unexamined.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## ADVERSARIAL REVIEW AND APPROVAL

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14. This is the 9 October 2026 revised edition; findings are marked where the 9 October revision introduced the defect rather than inheriting it.

**Scope of checks.** All 61 REFERENCES PMIDs verified against PubMed metadata (61/61 resolve to the stated first author, year, journal and title; 0 failures, 0 substitutions). The three in-text identifiers carried as status flags were verified against the PubMed CommentsCorrections elements and are correct: PMID 33649505 is the publisher correction to Shoshani 2021 *Nature*, PMID 42321512 the author correction to Nassour 2019 *Nature*, and PMID 36711674 the bioRxiv preprint that Girish 2023 *Science* updates. No reference carries a retraction or expression of concern. 14 load-bearing claims were spot-checked against the original abstracts, including the Silk 2013 rate-stratification result (low missegregation rates promoting and high rates suppressing tumours, with CENP-E-dependent missegregation leaving Ink4a-loss and Mlh1-reduction tumours unaffected), the Levine 2017 versus Vitre 2015 centrosome contrast, the Zhang 2012 USP44 result (spontaneous tumours particularly in lung; segregation control through direct centrin binding and spindle geometry, separable from the mitotic checkpoint), Bakhoum 2018, Li 2023 and Li 2021 on the CIN–cGAS/STING metastasis programme, Girish 2023 on 1q/MDM4 dependency, Rao 2005 on BubR1+/-ApcMin/+, and Sotillo 2010 on Kras/Mad2 relapse. All matched. Scoring logic was re-derived against `references/hsef-framework.md` and SKILL.md Step 3.

| ID | Severity | Location | Original → corrected | Evidence |
|---|---|---|---|---|
| AR-1 | Major — **revision-introduced regression** | Spliced "Consensus provenance reconciliation — 9 October 2026" block, closing paragraph (and `consensus-addendum.md`) | "The earlier adversarial approval refers to its original edition; this provenance supplement is not a new independent or blinded adjudication." → "No earlier adversarial approval is attached to this case; this provenance supplement is not a new independent or blinded adjudication, and nothing earlier certifies it." | No adversarial approval exists for this case. The original edition at `hsef_v53_popularity_ranks_36_40_2026-10-08/genome-instability-cancer/` carries none, and no approval statement appears anywhere in that batch. The 9 October integration asserted one unconditionally. Rescoped rather than deleted, so the disclaimer's purpose survives. |
| AR-2 | Major | AT A GLANCE table; "Final score, causal direction and M/S/D"; scorecard `extended_scoring_MSD.momentum` | Momentum "Decisive work underway" → "Mechanistic only" | The framework defines "Decisive work underway" as *someone running an experiment that could cross the next threshold*, with a named artifact. The artifact here names two **completed 2025 publications** (PMID 40670783, 41162705) that the review itself lists in its own examined inventory, and neither addresses the general-primacy boundary check that SC4 turns on. The same block's Stability entry already states that "no specific pending result is claimed to move the general-root grade imminently", which contradicts the stronger momentum value. "Mechanistic only" — active mechanistic work, nothing addressing the boundary check — is the correct value. Momentum modifies no letter, so Γ / Moderate are unchanged. |
| AR-3 | Minor | Throughout (AT A GLANCE, competing models, evidence narrative, evidence cards) | 63 renderer-dropped spaces repaired: 33 parenthetical citation groups, e.g. "(PMID24133140,28132847,26578792,34266887)" → "(PMID 24133140, 28132847, 26578792, 34266887)"; 29 link texts, "[PMID10608877](…)" → "[PMID 10608877](…)"; and "11 of24 double-inducible animals" → "11 of 24". | Known upstream rendering defect. Whitespace only; no identifier, number or wording altered, and the `Study: PMID…` study-identifier tokens were deliberately left as they are, being identifiers rather than citations. |
| AR-4 | Minor | REFERENCES 36, 52, 54, 56 | "DOI: ." → "No DOI in PubMed record." | Verified against the PubMed XML: PMID 11861370, 8674041, 9973196 and 8706033 carry no DOI ArticleId. The empty field was a rendering artifact, not a failed lookup. |
| AR-5 | Minor | Evidence cards for PMID 33361815, 30675059, 37410869 | "ErratumIn: PMID33649505." / "ErratumIn: PMID42321512." / "UpdateOf: PMID36711674." → "Erratum in: Nature. 2021 Mar;591(7850):E19 (PMID 33649505)." / "Erratum in: Nature. 2026 Jul;655(8122):E3 (PMID 42321512)." / "Update of: bioRxiv. 2023 Jan 10:2023.01.09.523344 (PMID 36711674)." | The citations now travel with the flags, as the citation-ledger rule requires ("The correction's own identifier goes in the flag text so it stays traceable"), and each was read off the parent record's own CommentsCorrections element. |
| AR-6 | Minor | scorecard `final_score.confidence_rationale` (3 occurrences) | "density, heterogeneous controls and incomplete access set the confidence" → "evidence density, heterogeneous controls and the predominance of engineered and transplant models set the confidence, not correctness and not reviewer access depth" | Applied under the lead's two-step confidence policy of 2026-10-14. Step 1 strikes access depth: `hsef-framework.md` defines the band by evidence density and reproducibility, not by how much of a paper the reviewer read. Step 2 re-derives the band, which stands at Moderate, because access depth was not the only thing holding it down — the review documents substantive evidence-quality reservations of its own throughout (engineered and transplant rather than autochthonous models, shared programmes and model families counted as one line, coupled gene functions and pleiotropy, and the absence of any matched independent rate-restoration course test). That is the framework's Moderate text, not its High text. |

**Rejected findings (checked, no change).**
1. **Headline Γ.** Argued up to Ε on the strength of SC3, and up to Ζ on the strength of SC2. Both rejected on the aggregation rule as written. Primary-subclaim was pre-registered on SC4, the general-root gate, which is Γ. The two reported sensitivities are also correct as printed: weakest-link returns Β because SC1 is Β, and scope-matched returns Γ because SC4 is the only subclaim whose scope — "representative prespecified cancer etiologies and stages" — matches the central claim's general scope, while SC2 is restricted to a specific lesion and tissue genotype and SC3 is an Ε and therefore scope-restricted by definition. This is exactly the misreading the round-2 brief warns about, and the review does not commit it.
2. **SC2 at Ζ.** Checked against the v5.2 shared-failure test and the requirement that Ζ carry a recorded independence basis. One is recorded, naming endogenous MMR susceptibility, repair-domain models and segregation-specific genetic contexts, with the shared-line caveats stated (follow-up mice sharing the founding line; coupled gene functions). Different repair proteins and different lineages are not defeated by a single systematic error. No change.
3. **Causal role "reinforcing / stabilizing factor".** Re-derived through the framework's ordered procedure. Step 3 fails because the evidence does not show instability is rate-limiting for the general phenotype, and step 4 fails because it is not required for the phenotype; the mechanism amplifies and accelerates a phenotype initiated upstream. Step 5 is correct.
4. **"Best-supported rival."** Verified against the scorecard: `models_evaluated[0]` is rank 1 with `is_nominal: false`; the nominal "General instability-first root" is rank 5 at Γ. The known renderer defect that prints the nominal as the rival does not fire here.
5. **Divergence "Contested" with a null implied level.** Permitted by the framework, which allows Contested where the field is genuinely split and no single implied level applies, and the scorecard records that basis explicitly rather than leaving the field blank.
6. **The tournament's effect on the letter.** The review states that the tournament does not alter the nominal level, which is correct: winning the tournament does not imply primary driver, and here the nominal does not even win.
7. **Collective authors.** The one CollectiveName in the set (TRACERx consortium, PMID 38871738) is absorbed into "et al."; no reference begins with a stray comma.

**Residual limitations.** 53 of 61 records were examined at complete-abstract/status depth, so the numeric checks above rest on abstracts and the eight examined bodies. The review records two linked correction details as unexamined in substance; this reviewer resolved their citations but did not read their content either. `provenance_header.generated_by` reads "Codex; HSEF v5.3" rather than naming Sol 6.1; this is a package-wide field and was left for the lead. The divergent copy at `hsef_v53_popularity_ranks_36_40_2026-10-08/genome-instability-cancer/` was deliberately not touched.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

## REFERENCES

1. Li J, Hubisz MJ, Earlie EM et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature. 2023. [PMID 37612508](https://pubmed.ncbi.nlm.nih.gov/37612508/). DOI: 10.1038/s41586-023-06464-z. Access: full_text_partial. Study: PMID37612508.

2. Bakhoum SF, Ngo B, Laughney AM et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018. [PMID 29342134](https://pubmed.ncbi.nlm.nih.gov/29342134/). DOI: 10.1038/nature25432. Access: full_text_partial. Study: PMID29342134.

3. Li J, Duran MA, Dhanota N et al. Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer discovery. 2021. [PMID 33372007](https://pubmed.ncbi.nlm.nih.gov/33372007/). DOI: 10.1158/2159-8290.CD-20-0387. Access: abstract_metadata. Study: PMID33372007.

4. Watkins TBK, Lim EL, Petkovic M et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature. 2020. [PMID 32879494](https://pubmed.ncbi.nlm.nih.gov/32879494/). DOI: 10.1038/s41586-020-2698-6. Access: abstract_metadata. Study: PMID32879494.

5. McPherson A, Vázquez-García I, Myers MA et al. Ongoing genome doubling shapes evolvability and immunity in ovarian cancer. Nature. 2025. [PMID 40670783](https://pubmed.ncbi.nlm.nih.gov/40670783/). DOI: 10.1038/s41586-025-09240-3. Access: abstract_metadata. Study: PMID40670783.

6. Zasadil LM, Britigan EM, Ryan SD et al. High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation. Molecular biology of the cell. 2016. [PMID 27146113](https://pubmed.ncbi.nlm.nih.gov/27146113/). DOI: 10.1091/mbc.E15-10-0747. Access: abstract_metadata. Study: PMID27146113.

7. Silk AD, Zasadil LM, Holland AJ et al. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. Proceedings of the National Academy of Sciences of the United States of America. 2013. [PMID 24133140](https://pubmed.ncbi.nlm.nih.gov/24133140/). DOI: 10.1073/pnas.1317042110. Access: full_text_partial. Study: PMID24133140.

8. Zhang Y, Foreman O, Wigle DA et al. USP44 regulates centrosome positioning to prevent aneuploidy and suppress tumorigenesis. The Journal of clinical investigation. 2012. [PMID 23187126](https://pubmed.ncbi.nlm.nih.gov/23187126/). DOI: 10.1172/JCI63084. Access: abstract_metadata. Study: PMID23187126.

9. Giaretti W, Venesio T, Prevosto C et al. Chromosomal instability and APC gene mutations in human sporadic colorectal adenomas. The Journal of pathology. 2004. [PMID 15376262](https://pubmed.ncbi.nlm.nih.gov/15376262/). DOI: 10.1002/path.1623. Access: abstract_metadata. Study: PMID15376262.

10. Rao CV, Yang YM, Swamy MV et al. Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proceedings of the National Academy of Sciences of the United States of America. 2005. [PMID 15767571](https://pubmed.ncbi.nlm.nih.gov/15767571/). DOI: 10.1073/pnas.0407822102. Access: abstract_metadata. Study: PMID15767571.

11. Drews RM, Hernando B, Tarabichi M et al. A pan-cancer compendium of chromosomal instability. Nature. 2022. [PMID 35705807](https://pubmed.ncbi.nlm.nih.gov/35705807/). DOI: 10.1038/s41586-022-04789-9. Access: abstract_metadata. Study: PMID35705807.

12. Nassour J, Radford R, Correia A et al. Autophagic cell death restricts chromosomal instability during replicative crisis. Nature. 2019. [PMID 30675059](https://pubmed.ncbi.nlm.nih.gov/30675059/). DOI: 10.1038/s41586-019-0885-0. Access: abstract_metadata. Study: PMID30675059.

13. Lukow DA, Sausville EL, Suri P et al. Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. Developmental cell. 2021. [PMID 34352222](https://pubmed.ncbi.nlm.nih.gov/34352222/). DOI: 10.1016/j.devcel.2021.07.009. Access: abstract_metadata. Study: PMID34352222.

14. Bronder D, Tighe A, Wangsa D et al. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells. Disease models & mechanisms. 2021. [PMID 34569598](https://pubmed.ncbi.nlm.nih.gov/34569598/). DOI: 10.1242/dmm.049001. Access: abstract_metadata. Study: PMID34569598.

15. Hobor S, Al Bakir M, Hiley CT et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nature communications. 2024. [PMID 38871738](https://pubmed.ncbi.nlm.nih.gov/38871738/). DOI: 10.1038/s41467-024-47606-9. Access: abstract_metadata. Study: PMID38871738.

16. Cosenza MR, Gaiatto A, Erarslan Uysal B et al. Origins of chromosome instability unveiled by coupled imaging and genomics. Nature. 2025. [PMID 41162705](https://pubmed.ncbi.nlm.nih.gov/41162705/). DOI: 10.1038/s41586-025-09632-5. Access: abstract_metadata. Study: PMID41162705.

17. Gong Y, Zou S, Deng D et al. Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma. Developmental cell. 2023. [PMID 36696903](https://pubmed.ncbi.nlm.nih.gov/36696903/). DOI: 10.1016/j.devcel.2022.12.012. Access: abstract_metadata. Study: PMID36696903.

18. Salgueiro L, Buccitelli C, Rowald K et al. Acquisition of chromosome instability is a mechanism to evade oncogene addiction. EMBO molecular medicine. 2020. [PMID 32030896](https://pubmed.ncbi.nlm.nih.gov/32030896/). DOI: 10.15252/emmm.201910941. Access: abstract_metadata. Study: PMID32030896.

19. Crowley EA, Hermance NM, Herlihy CP et al. Suppression of Chromosome Instability Limits Acquired Drug Resistance. Molecular cancer therapeutics. 2022. [PMID 35905505](https://pubmed.ncbi.nlm.nih.gov/35905505/). DOI: 10.1158/1535-7163.MCT-22-0263. Access: abstract_metadata. Study: PMID35905505.

20. Gao C, Su Y, Koeman J et al. Chromosome instability drives phenotypic switching to metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2016. [PMID 27930335](https://pubmed.ncbi.nlm.nih.gov/27930335/). DOI: 10.1073/pnas.1618215113. Access: abstract_metadata. Study: PMID27930335.

21. Saavedra HI, Fukasawa K, Conn CW et al. MAPK mediates RAS-induced chromosome instability. The Journal of biological chemistry. 1999. [PMID 10608877](https://pubmed.ncbi.nlm.nih.gov/10608877/). DOI: 10.1074/jbc.274.53.38083. Access: abstract_metadata. Study: PMID10608877.

22. Girish V, Lakhani AA, Thompson SL et al. Oncogene-like addiction to aneuploidy in human cancers. Science (New York, N.Y.). 2023. [PMID 37410869](https://pubmed.ncbi.nlm.nih.gov/37410869/). DOI: 10.1126/science.adg4521. Access: abstract_metadata. Study: PMID37410869.

23. Balbás-Martínez C, Sagrera A, Carrillo-de-Santa-Pau E et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nature genetics. 2013. [PMID 24121791](https://pubmed.ncbi.nlm.nih.gov/24121791/). DOI: 10.1038/ng.2799. Access: abstract_metadata. Study: PMID24121791.

24. Williams BR, Prabhu VR, Hunter KE et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science (New York, N.Y.). 2008. [PMID 18974345](https://pubmed.ncbi.nlm.nih.gov/18974345/). DOI: 10.1126/science.1160058. Access: abstract_metadata. Study: PMID18974345.

25. Pfau SJ, Silberman RE, Knouse KA et al. Aneuploidy impairs hematopoietic stem cell fitness and is selected against in regenerating tissues in vivo. Genes & development. 2016. [PMID 27313317](https://pubmed.ncbi.nlm.nih.gov/27313317/). DOI: 10.1101/gad.278820.116. Access: abstract_metadata. Study: PMID27313317.

26. Zheng L, Dai H, Hegde ML et al. Fen1 mutations that specifically disrupt its interaction with PCNA cause aneuploidy-associated cancer. Cell research. 2011. [PMID 21383776](https://pubmed.ncbi.nlm.nih.gov/21383776/). DOI: 10.1038/cr.2011.35. Access: abstract_metadata. Study: PMID21383776.

27. Weaver BA, Silk AD, Montagna C et al. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer cell. 2007. [PMID 17189716](https://pubmed.ncbi.nlm.nih.gov/17189716/). DOI: 10.1016/j.ccr.2006.12.003. Access: abstract_metadata. Study: PMID17189716.

28. Rohban S, Cerutti A, Morelli MJ et al. The cohesin complex prevents Myc-induced replication stress. Cell death & disease. 2017. [PMID 28749464](https://pubmed.ncbi.nlm.nih.gov/28749464/). DOI: 10.1038/cddis.2017.345. Access: abstract_metadata. Study: PMID28749464.

29. Kanu N, Cerone MA, Goh G et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome biology. 2016. [PMID 27634334](https://pubmed.ncbi.nlm.nih.gov/27634334/). DOI: 10.1186/s13059-016-1042-9. Access: abstract_metadata. Study: PMID27634334.

30. Lee SA, Lee HS, Hur SK et al. INO80 haploinsufficiency inhibits colon cancer tumorigenesis via replication stress-induced apoptosis. Oncotarget. 2017. [PMID 29383140](https://pubmed.ncbi.nlm.nih.gov/29383140/). DOI: 10.18632/oncotarget.22984. Access: abstract_metadata. Study: PMID29383140.

31. Guan J, Lu C, Jin Q et al. MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway. Cancer cell. 2021. [PMID 33338427](https://pubmed.ncbi.nlm.nih.gov/33338427/). DOI: 10.1016/j.ccell.2020.11.004. Access: abstract_metadata. Study: PMID33338427.

32. Amodio V, Lamba S, Chilà R et al. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer cell. 2023. [PMID 36584674](https://pubmed.ncbi.nlm.nih.gov/36584674/). DOI: 10.1016/j.ccell.2022.12.003. Access: abstract_metadata. Study: PMID36584674.

33. Lu C, Guan J, Lu S et al. DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer cell. 2021. [PMID 33338425](https://pubmed.ncbi.nlm.nih.gov/33338425/). DOI: 10.1016/j.ccell.2020.11.006. Access: abstract_metadata. Study: PMID33338425.

34. Springuel L, Losdyck E, Saussoy P et al. Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases. Cellular and molecular life sciences : CMLS. 2016. [PMID 27436342](https://pubmed.ncbi.nlm.nih.gov/27436342/). DOI: 10.1007/s00018-016-2310-2. Access: abstract_metadata. Study: PMID27436342.

35. Deng CX et al. Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. Mutation research. 2001. [PMID 11376699](https://pubmed.ncbi.nlm.nih.gov/11376699/). DOI: 10.1016/s0027-5107(01)00119-1. Access: abstract_metadata. Study: PMID11376699.

36. McAllister KA, Bennett LM, Houle CD et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer research. 2002. [PMID 11861370](https://pubmed.ncbi.nlm.nih.gov/11861370/). No DOI in PubMed record. Access: abstract_metadata. Study: PMID11861370.

37. Sotillo R, Hernando E, Díaz-Rodríguez E et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer cell. 2007. [PMID 17189715](https://pubmed.ncbi.nlm.nih.gov/17189715/). DOI: 10.1016/j.ccr.2006.10.019. Access: full_text_partial. Study: PMID17189715.

38. Shoshani O, Bakker B, de Haan L et al. Transient genomic instability drives tumorigenesis through accelerated clonal evolution. Genes & development. 2021. [PMID 34266887](https://pubmed.ncbi.nlm.nih.gov/34266887/). DOI: 10.1101/gad.348319.121. Access: full_text_partial. Study: PMID34266887.

39. Morales JC, Franco S, Murphy MM et al. 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 2006. [PMID 16492765](https://pubmed.ncbi.nlm.nih.gov/16492765/). DOI: 10.1073/pnas.0511259103. Access: abstract_metadata. Study: PMID16492765.

40. Saavedra HI, Knauf JA, Shirokawa JM et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene. 2000. [PMID 10951588](https://pubmed.ncbi.nlm.nih.gov/10951588/). DOI: 10.1038/sj.onc.1203723. Access: abstract_metadata. Study: PMID10951588.

41. Vitre B, Holland AJ, Kulukian A et al. Chronic centrosome amplification without tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 2015. [PMID 26578792](https://pubmed.ncbi.nlm.nih.gov/26578792/). DOI: 10.1073/pnas.1519388112. Access: full_text_partial. Study: PMID26578792.

42. Levine MS, Bakker B, Boeckx B et al. Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals. Developmental cell. 2017. [PMID 28132847](https://pubmed.ncbi.nlm.nih.gov/28132847/). DOI: 10.1016/j.devcel.2016.12.022. Access: full_text_partial. Study: PMID28132847.

43. Basto R, Brunk K, Vinadogrova T et al. Centrosome amplification can initiate tumorigenesis in flies. Cell. 2008. [PMID 18555779](https://pubmed.ncbi.nlm.nih.gov/18555779/). DOI: 10.1016/j.cell.2008.05.039. Access: abstract_metadata. Study: PMID18555779.

44. Godinho SA, Picone R, Burute M et al. Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014. [PMID 24739973](https://pubmed.ncbi.nlm.nih.gov/24739973/). DOI: 10.1038/nature13277. Access: abstract_metadata. Study: PMID24739973.

45. Engel JL, Zhang X, Wu M et al. The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance. Cell. 2024. [PMID 39181133](https://pubmed.ncbi.nlm.nih.gov/39181133/). DOI: 10.1016/j.cell.2024.08.001. Access: abstract_metadata. Study: PMID39181133.

46. Espejo Valle-Inclan J, De Noon S, Trevers K et al. Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution. Cell. 2025. [PMID 39814020](https://pubmed.ncbi.nlm.nih.gov/39814020/). DOI: 10.1016/j.cell.2024.12.005. Access: abstract_metadata. Study: PMID39814020.

47. Shoshani O, Brunner SF, Yaeger R et al. Chromothripsis drives the evolution of gene amplification in cancer. Nature. 2021. [PMID 33361815](https://pubmed.ncbi.nlm.nih.gov/33361815/). DOI: 10.1038/s41586-020-03064-z. Access: abstract_metadata. Study: PMID33361815.

48. Zhang CZ, Spektor A, Cornils H et al. Chromothripsis from DNA damage in micronuclei. Nature. 2015. [PMID 26017310](https://pubmed.ncbi.nlm.nih.gov/26017310/). DOI: 10.1038/nature14493. Access: abstract_metadata. Study: PMID26017310.

49. Di Micco R, Fumagalli M, Cicalese A et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006. [PMID 17136094](https://pubmed.ncbi.nlm.nih.gov/17136094/). DOI: 10.1038/nature05327. Access: abstract_metadata. Study: PMID17136094.

50. Bartkova J, Horejsí Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005. [PMID 15829956](https://pubmed.ncbi.nlm.nih.gov/15829956/). DOI: 10.1038/nature03482. Access: abstract_metadata. Study: PMID15829956.

51. Bartkova J, Rezaei N, Liontos M et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006. [PMID 17136093](https://pubmed.ncbi.nlm.nih.gov/17136093/). DOI: 10.1038/nature05268. Access: abstract_metadata. Study: PMID17136093.

52. Reitmair AH, Cai JC, Bjerknes M et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer research. 1996. [PMID 8674041](https://pubmed.ncbi.nlm.nih.gov/8674041/). No DOI in PubMed record. Access: abstract_metadata. Study: PMID8674041.

53. Andrew SE, Reitmair AH, Fox J et al. Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice. Oncogene. 1997. [PMID 9244348](https://pubmed.ncbi.nlm.nih.gov/9244348/). DOI: 10.1038/sj.onc.1201180. Access: abstract_metadata. Study: PMID9244348.

54. Buermeyer AB, Wilson-Van Patten C, Baker SM et al. The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts. Cancer research. 1999. [PMID 9973196](https://pubmed.ncbi.nlm.nih.gov/9973196/). No DOI in PubMed record. Access: abstract_metadata. Study: PMID9973196.

55. de Wind N, Dekker M, Berns A et al. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell. 1995. [PMID 7628020](https://pubmed.ncbi.nlm.nih.gov/7628020/). DOI: 10.1016/0092-8674(95)90319-4. Access: abstract_metadata. Study: PMID7628020.

56. Reitmair AH, Redston M, Cai JC et al. Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer research. 1996. [PMID 8706033](https://pubmed.ncbi.nlm.nih.gov/8706033/). No DOI in PubMed record. Access: abstract_metadata. Study: PMID8706033.

57. Dai W, Wang Q, Liu T et al. Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency. Cancer research. 2004. [PMID 14744753](https://pubmed.ncbi.nlm.nih.gov/14744753/). DOI: 10.1158/0008-5472.can-03-3119. Access: abstract_metadata. Study: PMID14744753.

58. Park I, Lee HO, Choi E et al. Loss of BubR1 acetylation causes defects in spindle assembly checkpoint signaling and promotes tumor formation. The Journal of cell biology. 2013. [PMID 23878276](https://pubmed.ncbi.nlm.nih.gov/23878276/). DOI: 10.1083/jcb.201210099. Access: abstract_metadata. Study: PMID23878276.

59. Ricke RM, Jeganathan KB, Malureanu L et al. Bub1 kinase activity drives error correction and mitotic checkpoint control but not tumor suppression. The Journal of cell biology. 2012. [PMID 23209306](https://pubmed.ncbi.nlm.nih.gov/23209306/). DOI: 10.1083/jcb.201205115. Access: abstract_metadata. Study: PMID23209306.

60. Weaver RL, Limzerwala JF, Naylor RM et al. BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer. eLife. 2016. [PMID 27528194](https://pubmed.ncbi.nlm.nih.gov/27528194/). DOI: 10.7554/eLife.16620. Access: abstract_metadata. Study: PMID27528194.

61. Sotillo R, Schvartzman JM, Socci ND et al. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature. 2010. [PMID 20173739](https://pubmed.ncbi.nlm.nih.gov/20173739/). DOI: 10.1038/nature08803. Access: full_text_partial. Study: PMID20173739.

## Source-specific evidence cards

### [1] Non-cell-autonomous cancer progression from chromosomal instability.

**Shows:** CIN rate and cGAS-STING/ER-stress perturbations alter metastasis through host immune context.

**Does not show:** Same Bakhoum programme as 2018; engineered transplant models establish progression not all-cancer initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Immune dependence of CIN-driven metastasis, 6:STING inhibitors suppress metastasis. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [2] Chromosomal instability drives metastasis through a cytosolic DNA response.

**Shows:** KIF2B/MCAK lower measured missegregation without normalizing aneuploid burden; metastasis falls and Mad2 partially restores it.

**Does not show:** Primary growth does not consistently fall; forced rate correction and transplantation do not establish universal endogenous initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:CIN is a driver of metastasis, 3:CIN generates cytosolic DNA, 4:Metastasis from cytosolic DNA response. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [3] Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.

**Shows:** ENPP1 loss and host STING epistasis link extracellular cGAMP handling to metastasis and immune recruitment.

**Does not show:** Downstream immune mechanism rather than proof that CIN initiates cancer; shared programme.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [4] Pervasive chromosomal instability and karyotype order in tumour evolution.

**Shows:** Phased copy-number evolution supports ongoing and parallel alteration histories.

**Does not show:** Historical inference from sampled genomes is not directly measured per-division missegregation or initiating perturbation; cohort overlap.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [5] Ongoing genome doubling shapes evolvability and immunity in ovarian cancer.

**Shows:** Whole-genome-doubling trajectories and imaging reveal heterogeneous ongoing instability states.

**Does not show:** Selected human tumors; temporal reconstruction and immune-state associations do not establish initiating primacy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [6] High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation.

**Shows:** High chromosome missegregation suppresses later progression while permitting initiating organoids.

**Does not show:** Rate and stage dependent; shared CENP-E programme, not evidence against every low-rate contribution.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [7] Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors.

**Shows:** Combined high missegregation raises cell death and reduces tumors; extra CENP-E-dependent CIN has no tumor effect in Ink4a or MLH1 contexts.

**Does not show:** Genetic background, rate and tissue matter; this discriminating negative does not enter a positive-support tally.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Publisher HTML paragraphs:paragraph30, 0:Publisher HTML paragraphs:paragraph31, 0:Publisher HTML paragraphs:paragraph32, 0:Publisher HTML paragraphs:paragraph34, 0:Publisher HTML paragraphs:paragraph35, 0:Publisher HTML paragraphs:paragraph36, 0:Publisher HTML paragraphs:paragraph37, 0:Publisher HTML paragraphs:paragraph38, 0:Publisher HTML paragraphs:paragraph40, 0:Publisher HTML paragraphs:paragraph50. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC4.

### [8] USP44 regulates centrosome positioning to prevent aneuploidy and suppress tumorigenesis.

**Shows:** USP44 loss causes segregation defects and spontaneous lung tumors; centrin interaction separates centrosome positioning from checkpoint delay.

**Does not show:** USP44 has multiple functions; endogenous model supports a defined initiating route, not a general root.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [9] Chromosomal instability and APC gene mutations in human sporadic colorectal adenomas.

**Shows:** APC mutation subgroups associate with aneuploid burden.

**Does not show:** Overall APC relationship is weak; cross-sectional burden is not a rate measurement or a causal intervention.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [10] Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability.

**Shows:** BubR1 insufficiency increases chromosome errors and colon tumor incidence and grade with an Apc driver.

**Does not show:** Genetic interaction and checkpoint functions are coupled; no claim that instability alone initiates all cancers.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [11] A pan-cancer compendium of chromosomal instability.

**Shows:** Copy-number signatures distinguish putative processes across thousands of tumors.

**Does not show:** Static patterns and inferred etiologies do not directly measure rates, precedence or necessity.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [12] Autophagic cell death restricts chromosomal instability during replicative crisis.

**Shows:** cGAS-STING/autophagy removes crisis cells; suppressing the barrier permits unstable proliferating cells.

**Does not show:** Cell culture and telomere manipulation; linked erratum details unexamined; supports a barrier, not universal tumor suppression.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Erratum in: Nature. 2026 Jul;655(8122):E3 (PMID 42321512). Subclaims: SC2, SC4.

### [13] Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies.

**Shows:** Transient CIN generates recurrent aneuploid resistant clones; a specified chromosome loss confers paclitaxel resistance.

**Does not show:** Fixed resistant state is distinct from continued rate dependence; selected treatment context.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [14] TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.

**Shows:** p53 loss precedes induced CIN, with BRCA1 and MYC adding instability.

**Does not show:** Nontransformed cultures rather than autochthonous initiation; demonstrates a plausible upstream-driver direction.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

### [15] Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling.

**Shows:** Whole-genome doubling and copy-number routes alter targeted-treatment responses.

**Does not show:** Treatment-selected evolution and existing drivers; not untreated initiating primacy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [16] Origins of chromosome instability unveiled by coupled imaging and genomics.

**Shows:** Direct division-to-genome measurements identify new abnormalities and increased rates with TP53 defects.

**Does not show:** Near-diploid cultured cells; downstream driver perturbation rather than human initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [17] Loss of RanGAP1 drives chromosome instability and rapid tumorigenesis of osteosarcoma.

**Shows:** RanGAP1 dysregulation couples mitotic disruption, chromothripsis, Rb1 disruption and rapid osteosarcoma.

**Does not show:** Protein transport, p53 degradation and segregation are coupled; the initiating mechanism is not isolated instability alone.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [18] Acquisition of chromosome instability is a mechanism to evade oncogene addiction.

**Shows:** CIN promotes escape through MET amplification and creates a new cMet dependency.

**Does not show:** Established oncogene-driven and withdrawal-selected disease; not original initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [19] Suppression of Chromosome Instability Limits Acquired Drug Resistance.

**Shows:** Reducing CIN changes resistance timing and copy-number routes without changing initial xenograft growth.

**Does not show:** Resistance-specific engineered models; transplant growth alone cannot establish endogenous initiating necessity.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [20] Chromosome instability drives phenotypic switching to metastasis.

**Shows:** Chromosome-content changes accompany EMT/reversion with ZEB1 functional interventions.

**Does not show:** State-selection experiments and transcriptional effects do not isolate ongoing CIN as the sole driver.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [21] MAPK mediates RAS-induced chromosome instability.

**Shows:** RAS/MAPK activation produces micronuclei, reversed by MEK-pathway inhibition.

**Does not show:** Forced expression and cultured cells; upstream oncogene can cause instability but this does not quantify all sporadic tumors.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [22] Oncogene-like addiction to aneuploidy in human cancers.

**Shows:** Removing recurrent trisomy 1q impairs malignant growth through an MDM4-p53 axis.

**Does not show:** Dependency on a fixed chromosome state is not dependence on the rate of genome change.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Update of: bioRxiv. 2023 Jan 10:2023.01.09.523344 (PMID 36711674). Subclaims: SC3.

### [23] Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy.

**Shows:** STAG2 loss can affect tumor suppression without aneuploidy or increased aneuploidy after knockdown.

**Does not show:** Gene pleiotropy and cancer lineage; repair/segregation gene lesions cannot automatically be assigned to CIN.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [24] Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells.

**Shows:** Specified trisomies impair proliferation and alter metabolism.

**Does not show:** Static chromosome states and cultured cells; does not negate every adaptive aneuploidy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [25] Aneuploidy impairs hematopoietic stem cell fitness and is selected against in regenerating tissues in vivo.

**Shows:** Aneuploidy and CIN impair regenerative fitness in vivo.

**Does not show:** Regeneration/transplant challenge is not spontaneous tumor initiation; tissue selection boundary.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [26] Fen1 mutations that specifically disrupt its interaction with PCNA cause aneuploidy-associated cancer.

**Shows:** Defective PCNA interaction compromises replication/repair and increases instability, transformation and tumors.

**Does not show:** Repair, replication and checkpoint functions change together; cell-level Chk1 inhibition is not whole-animal repair restoration.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [27] Aneuploidy acts both oncogenically and as a tumor suppressor.

**Shows:** Defined tissues show spontaneous tumor promotion while other contexts show suppression.

**Does not show:** Abstract-only; tissue-specific opposing outcomes and shared CENP-E model family limit generalization.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [28] The cohesin complex prevents Myc-induced replication stress.

**Shows:** Transcriptional rescue fails to normalize replication stress and S-phase defects.

**Does not show:** Cultured cells and cohesin pleiotropy; separates transcription from replication, not general initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [29] DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.

**Shows:** Oncogenic signaling induces replication stress/APOBEC activity, reduced by RTK inhibition or nucleosides.

**Does not show:** Enzyme activity is not a measured longitudinal mutation rate or organismal tumor-course rescue.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [30] INO80 haploinsufficiency inhibits colon cancer tumorigenesis via replication stress-induced apoptosis.

**Shows:** Increased fork stress and checkpoint apoptosis reduce polyps and improve survival.

**Does not show:** Existing Apc driver and repair-protein pleiotropy; excess instability/stress may suppress rather than initiate.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [31] MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway.

**Shows:** Exo1-dependent hyperexcision links MMR loss to cytosolic DNA and STING.

**Does not show:** Repair loss can trigger opposing immune consequences; not a universal tumor-promoting root.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [32] Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.

**Shows:** Increasing the dMMR fraction allows immune rejection in a defined mixture and treatment setting.

**Does not show:** Mixture threshold and immune context; does not imply prevention of all MMR-deficient tumors.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

### [33] DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity.

**Shows:** cGAS/STING governs priming and checkpoint response in repair-defective tumors.

**Does not show:** Downstream immune context and pre-established tumors; greater instability can favor host control.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [34] Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.

**Shows:** MLH1 manipulation changes resistant mutation frequencies and growth-factor/drug dependence.

**Does not show:** Cell restoration plus patient association do not establish prospective human tumor prevention.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [35] Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice.

**Shows:** Endogenous Brca1 loss predisposes mammary tumors with later cooperating alterations.

**Does not show:** Long latency and p53 mutations; essential repair, growth and apoptosis functions cannot be reduced to one rate.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [36] Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene.

**Shows:** Viable homozygous domain-mutant animals develop more tumors and shorter survival.

**Does not show:** Domain perturbation has coupled functions; no genotype-matched full repair restoration establishes all-cancer primacy.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [37] Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.

**Shows:** Mad2-induced instability promotes diverse tumors but 12 imaged tumors continue growing after Mad2 withdrawal.

**Does not show:** Forced expression and long latency; withdrawing the inducer does not prove all residual instability disappears.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Publisher HTML paragraphs:paragraph15, 0:Publisher HTML paragraphs:paragraph22, 0:Publisher HTML paragraphs:paragraph25, 0:Publisher HTML paragraphs:paragraph27, 0:Publisher HTML paragraphs:paragraph29, 0:Publisher HTML paragraphs:paragraph30. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

### [38] Transient genomic instability drives tumorigenesis through accelerated clonal evolution.

**Shows:** A short CIN pulse accelerates thymic lymphoma in p53-deficient contexts and yields selected karyotypes.

**Does not show:** Wild-type p53 mice show no survival/tumor increase; ongoing instability is not obligatory once selected states arise.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Results:paragraph2, 0:Results:paragraph3, 0:Results:paragraph4, 0:Results:paragraph5, 0:Results:paragraph7, 0:Results:paragraph9, 0:Results:paragraph17, 0:Results:paragraph18, 0:Results:paragraph20, 0:Results:paragraph24. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3, SC4.

### [39] 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis.

**Shows:** Combined endogenous repair/checkpoint defects accelerate lymphoma with structural and numerical errors.

**Does not show:** Genetic interaction with an existing driver; repair and checkpoint effects are coupled.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [40] The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway.

**Shows:** Activated RAS rapidly induces micronuclei through MAPK, with pathway-specific contrasts.

**Does not show:** Forced driver in culture; demonstrates upstream causation without assigning the frequency in human cancers.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [41] Chronic centrosome amplification without tumorigenesis.

**Shows:** Centrosome amplification and increased abnormal mitoses do not add tumors or shorten tumor-free survival in tested contexts.

**Does not show:** Exposure design, tissues, p53 surveillance and lethal competing tumors differ from positive Plk4 models.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Publisher HTML paragraphs:paragraph30, 0:Publisher HTML paragraphs:paragraph34, 0:Publisher HTML paragraphs:paragraph39, 0:Publisher HTML paragraphs:paragraph42, 0:Publisher HTML paragraphs:paragraph43, 0:Publisher HTML paragraphs:paragraph44, 0:Publisher HTML paragraphs:paragraph45, 0:Publisher HTML paragraphs:paragraph46, 0:Publisher HTML paragraphs:paragraph48, 0:Publisher HTML paragraphs:paragraph49. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [42] Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals.

**Shows:** Chronic or transient induction yields persistent centrosome amplification and spontaneous tumors; ApcMin tumor number rises.

**Does not show:** Forced inducible system; tissue expression varies, p53 signaling is partly compromised in tumors and CIN-specific pleiotropy is not entirely excluded.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph0, 1:RESULTS:paragraph4, 1:RESULTS:paragraph8, 1:RESULTS:paragraph9, 1:RESULTS:paragraph10, 1:RESULTS:paragraph11, 1:RESULTS:paragraph12, 1:RESULTS:paragraph13. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [43] Centrosome amplification can initiate tumorigenesis in flies.

**Shows:** Extra centrosomes disrupt asymmetric division and generate transplantable tumors despite stable diploid tissue genomes.

**Does not show:** Nonmammalian context; argues that centrosome effects can act outside a large CIN pathway.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

### [44] Oncogene-like induction of cellular invasion from centrosome amplification.

**Shows:** Centrosome amplification promotes invasion through microtubule/Rac1 changes.

**Does not show:** Cytoskeletal effects are distinct from genome-change rates; invasion in culture is not metastasis necessity.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [45] The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance.

**Shows:** Noncanonical Fanconi machinery promotes micronuclear fragmentation and ecDNA-associated resistance.

**Does not show:** Pathway effects differ between micronuclei and interphase nuclei; treatment-selected cell models.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [46] Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution.

**Shows:** Subclonal chromothripsis and amplification support continuing tumor evolution histories.

**Does not show:** Timing is reconstructed from samples rather than prospectively measured or causally corrected initiation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [47] Chromothripsis drives the evolution of gene amplification in cancer.

**Shows:** Chromothripsis generates ecDNA amplification and selectable resistance with DNA-repair perturbations.

**Does not show:** Treatment selection and cell models; linked erratum details unexamined.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. Erratum in: Nature. 2021 Mar;591(7850):E19 (PMID 33649505). Subclaims: SC3.

### [48] Chromothripsis from DNA damage in micronuclei.

**Shows:** Micronuclear replication/segregation can generate chromothripsis within one cell cycle.

**Does not show:** Demonstrates process capacity, not a general initiating or maintenance necessity in patients.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [49] Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication.

**Shows:** Oncogene-induced hyperreplication triggers a damage response and senescence barrier.

**Does not show:** Abstract-only original; upstream oncogene and barrier removal do not establish universal rates or endogenous initiating order.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [50] DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

**Shows:** DNA-damage signaling appears in early lesions and oncogene-driven models before overt instability.

**Does not show:** Cross-sectional human stages are not serial clonal trajectories; checkpoint activity can protect against cancer.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [51] Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints.

**Shows:** Disabling the damage response relaxes oncogene-induced senescence and increases invasive behavior.

**Does not show:** Checkpoint intervention changes survival and selection, not just mutation rate; tissue-specific experimental context.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

### [52] MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.

**Shows:** Repair deficiency accelerates adenomas and changes routes of Apc inactivation.

**Does not show:** Inherited Apc driver already present; not instability-alone initiation or all-cancer necessity.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [53] Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice.

**Shows:** Normal tissues accumulate greater reporter mutation frequencies after endogenous repair loss.

**Does not show:** Frequency per sampled tissue is not per-division rate; reporter and tissue selection limit generalization.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [54] The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts.

**Shows:** MLH1 restoration decreases substitution/microsatellite mutation and restores associated MMR functions.

**Does not show:** Repair rescue in cultured cells is not a prevention or regression experiment in tumors.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [55] Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.

**Shows:** Repair loss establishes a mutator/recombination phenotype and tumor susceptibility.

**Does not show:** Predisposition and essential repair changes do not identify instability as the sole immediate transforming lesion.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [56] Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice.

**Shows:** Lymphoma and intestinal tumors accrue with endogenous repair loss and Apc inactivation.

**Does not show:** Same Msh2 model family as 1995; not independent genetic replication or universal cancer causation.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [57] Slippage of mitotic arrest and enhanced tumor development in mice with BubR1 haploinsufficiency.

**Shows:** Checkpoint defects increase micronuclei and carcinogen-associated adenoma incidence.

**Does not show:** Carcinogen context and pleiotropic checkpoint function; spontaneous all-cancer root not tested.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [58] Loss of BubR1 acetylation causes defects in spindle assembly checkpoint signaling and promotes tumor formation.

**Shows:** A domain mutation weakens checkpoint/attachment fidelity and raises spontaneous tumor susceptibility.

**Does not show:** Mutant mimics a regulatory defect with multiple consequences and selected cooperating p53 changes.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [59] Bub1 kinase activity drives error correction and mitotic checkpoint control but not tumor suppression.

**Shows:** Substantial chromosome errors and aneuploidy occur without increased tumors in tested challenges.

**Does not show:** Modular endogenous negative evidence; genotype and measured error types matter, not all instability is tumor promoting.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

### [60] BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer.

**Shows:** Improving segregation fidelity protects against aneuploidy and cancer in tested contexts.

**Does not show:** Domain mechanisms and tissue scope differ from simple checkpoint-strength assumptions.

**Access/status:** Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [61] Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal.

**Shows:** Mad2 coexpression increases progression and later recurrence after both transgenes are withdrawn, without blocking initial Kras-dependent regression.

**Does not show:** Aneuploid burden at recurrence is not an ongoing measured rate; de novo recurrence cannot be formally excluded and model is forced.

**Access/status:** Complete primary abstract and linked-status metadata examined. Selected body sections: 3:Main text:paragraph0, 3:Main text:paragraph1, 3:Main text:paragraph3, 3:Main text:paragraph5, 3:Main text:paragraph6, 3:Main text:paragraph7, 3:Main text:paragraph8, 3:Main text:paragraph9, 3:Main text:paragraph10. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3, SC4.